drugset / Trial / NCT00969553

Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers

NCT00969553

Phase 1 Completed 59 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 in Asian cancer patients, and to provide safety data in terms of drug-related adverse events.

Timeline

Start
2009-08
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Volasertib Small molecule Intravenous

Indications